The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Open accessPublished version of a preprint
Abstract
Immunotherapeutic PD-1–targeted therapies require CD28 to promote cancer cell killing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ligation of PD-1 with its ligands programmed death-ligand 1 or 2 (PD-L1 or PD-L2) induces tyrosine phosphorylation of the PD-1 cytoplasmic domain by phosphorylating kinase Lck and subsequent recruitment of cytosolic tyrosine phosphatase SHP-2 and PD-1-associated SHP-2 preferentially dephosphorylates CD28 and suppresses CD28 costimulatory signaling leading to restrained effector T cell function (49”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overcoming such checkpoints through the use of therapeutic antibodies targeting the CTLA-4, PD-1, or PD-L1 cell-surface receptors was shown to be instrumental in promoting anti-tumor T cell responses in mice and in cancer patients”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Hui et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“SHP2 also has effects on parallel pathways (e.g., JAK/STAT signaling) and is implicated as an effector of inhibitory signaling by PD-1 and some other immune checkpoint receptors (Hui et al., 2017; Peled et al., 2018; Yokosuka et al., 2012).”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Hui et al., 2017
In the citing paper
“Among these, CD28 has recently been found to be the primary target (45).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [45]
In the citing paper
“The requirement for both T cell co-stimulation and IL-12 to achieve maximal IFN-γ response likely reflected the need of CD28 to rescue exhausted CD8+ T cells, and possibly also the role of PD-1 in limiting CD28-mediated co-stimulation (Kamphorst et al., 2017; Hui et al., 2017).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hui et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 1,002
Harnessing CD8 T cell responses using PD-1–IL-2 combination therapy
Hashimoto, M., Ramalingam, S. S., & Ahmed, R. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.11.008 · Cited by 57
Cytomegalovirus (CMV) Epitope–Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects
Abana, C. O., Pilkinton, M. A., Gaudieri, S., Chopra, A., McDonnell, W. J., Wanjalla, C. N., Barnett, L. D., Gangula, R., Hager, C. C., Jung, D. K., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700851 · Cited by 56
Ozay, E. I., Vijayaraghavan, J., González‐Pérez, G., Shanthalingam, S., Sherman, H. L., Garrigan, D. T., Chandiran, K., Torres, J. A., Osborne, B. A., Tew, G. N., et al. (2019) · Stem Cell Research · doi:10.1016/j.scr.2019.101401 · Cited by 55
Koumantou, D., Barnea, E., Martín‐Esteban, A., Maben, Z., Papakyriakou, A., Mpakali, A., Kokkala, P., Pratsinis, H., Georgiadis, D., Stern, L. J., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02358-0 · Cited by 52
New landscapes and horizons in hepatocellular carcinoma therapy
Cervello, M., Emma, M. R., Augello, G., Cusimano, A., Giannitrapani, L., Soresi, M., Akula, S. M., Abrams, S. L., Steelman, L. S., Gulino, A., et al. (2020) · Aging · doi:10.18632/aging.102777 · Cited by 56
PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy
DeRogatis, J. M., Viramontes, K. M., Neubert, E. N., & Tinoco, R. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636238 · Cited by 54
Off‐target inhibition by active site‐targeting SHP 2 inhibitors
Tsutsumi, R., Ran, H., & Neel, B. G. (2018) · FEBS Open Bio · doi:10.1002/2211-5463.12493 · Cited by 54
Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy
Zhao, L., & Fu, Z. (2018) · Journal of Immunology Research · doi:10.1155/2018/5301548 · Cited by 55
Vistain, L. F., Phan, H. V., Keisham, B., Jordi, C., Chen, M., Reddy, S. T., & Tay, S. (2022) · Nature Methods · doi:10.1038/s41592-022-01684-z · Cited by 57
Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma
Gabbia, D., & Martin, S. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043441 · Cited by 54
Signals that drive T follicular helper cell formation
Webb, L. M. C., & Linterman, M. A. (2017) · Immunology · doi:10.1111/imm.12778 · Cited by 55
Redirection to the bone marrow improves T cell persistence and antitumor functions
Khan, A. B., Carpenter, B., Sousa, P. S. E., Pospori, C., Khorshed, R., Griffin, J., Veliça, P., Zech, M., Ghorashian, S., Forrest, C., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97454 · Cited by 53
Escobar, G., Barbarossa, L., Barbiera, G., Norelli, M., Genua, M., Ranghetti, A., Plati, T., Camisa, B., Brombin, C., Cittaro, D., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05315-0 · Cited by 54
New Hope for Therapeutic Cancer Vaccines in the Era of Immune Checkpoint Modulation
Curran, M. A., & Glisson, B. S. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050217-121900 · Cited by 56
Immunotherapy in older patients with cancer
Granier, C., Gey, A., Roncelin, S., Weiss, L., Paillaud, É., & Tartour, É. (2020) · Biomedical Journal · doi:10.1016/j.bj.2020.07.009 · Cited by 58
Helpless Priming Sends CD8+ T Cells on the Road to Exhaustion
Busselaar, J., Tian, S., van Eenennaam, H., & Borst, J. G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.592569 · Cited by 57
Immune cellular components and signaling pathways in the tumor microenvironment
Yenyuwadee, S., Aliazis, K., Wang, Q., Christofides, A., Shah, R., Patsoukis, N., & Boussiotis, V. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.004 · Cited by 54
Cancer vaccines: translation from mice to human clinical trials
Maeng, H. M., Terabe, M., & Berzofsky, J. A. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.001 · Cited by 53
Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma
Veldman, J., Visser, L., van den Berg, A., & Diepstra, A. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101931 · Cited by 53
Combinatorial blockade for cancer immunotherapy: targeting emerging immune checkpoint receptors
Roy, D., Gilmour, C., Patnaik, S., & Wang, L. L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1264327 · Cited by 53
Ligtenberg, M. A., de Coaña, Y. P., Shmushkovich, T., Yoshimoto, Y., Truxová, I., Yang, Y., Betancur-Boissel, M., Eliseev, A. V., Wolfson, A. D., & Kiessling, R. W. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.04.015 · Cited by 53
Han, B., Dong, L., Zhou, J., Yang, Y., Guo, J., Xuan, Q., Gao, K., Xu, Z., Lei, W., Wang, J., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-02898-4 · Cited by 56
Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy
Ayala‐Mar, S., Donoso‐Quezada, J., & González‐Valdez, J. (2021) · Journal of Immunology Research · doi:10.1155/2021/8839978 · Cited by 52
The depths of PD-1 function within the tumor microenvironment beyond CD8+ T cells
Laba, S., Mallett, G., & Amarnath, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.022 · Cited by 54
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Michielin, O. A., Lalani, A. A., Robert, C., Sharma, P., & Peters, S. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003024 · Cited by 52
Zhang, K., Zakeri, A., Alban, T. J., Dong, J., Ta, H. M., Zalavadia, A. H., Branicky, A., Zhao, H., Jurić, I., Husic, H., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2023.113661 · Cited by 52
CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges
Zhou, Y., Wei, S., Xu, M., Wu, X., Dou, W., Li, H., Zhang, Z., & Zhang, S. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1489649 · Cited by 51
An organoid co-culture model for probing systemic anti-tumor immunity in lung cancer
Li, K., Liu, C., Sui, X., Li, C., Zhang, T., Zhao, T., Zhang, D., Wu, H., Liu, Y., Wang, S., et al. (2025) · Cell stem cell · doi:10.1016/j.stem.2025.05.011 · Cited by 59
Mechanisms of Primary and Secondary Resistance to Immune Checkpoint Inhibitors in Cancer
Seto, T., Sam, D. L., & Pan, M. (2019) · Medical Sciences · doi:10.3390/medsci7020014 · Cited by 52
Apatinib enhanced anti-PD-1 therapy for colon cancer in mice via promoting PD-L1 expression
Cai, X., Wei, B., Li, L., Chen, X., Liu, W., Cui, J. T., Lin, Y., Sun, Y., Xu, Q., Guo, W., et al. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106858 · Cited by 52
Autoimmune Endocrinopathies: An Emerging Complication of Immune Checkpoint Inhibitors
Quandt, Z., Young, A., Perdigoto, A. L., Herold, K. C., & Anderson, M. S. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-050219-034237 · Cited by 53
The double-edged sword: Harnessing PD-1 blockade in tumor and autoimmunity
Kuchroo, J. R., Hafler, D. A., Sharpe, A. H., & Lucca, L. E. (2021) · Science Immunology · doi:10.1126/sciimmunol.abf4034 · Cited by 51
Wang, R., Zhang, C., Cao, Y., Wang, J., Jiao, S., Zhang, J., Wang, M., Tang, P., Ouyang, Z., Liang, W., et al. (2022) · Theranostics · doi:10.7150/thno.79367 · Cited by 49
Chen, J., Fei, X., Wang, J., & Cai, Z. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105041 · Cited by 52
Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation
Sagawa, R., Sakata, S., Gong, B., Seto, Y., Takemoto, A., Takagi, S., Ninomiya, H., Yanagitani, N., Nakao, M., Mun, M., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.153323 · Cited by 50
Shaw, G. C., Cavalcante, L. L., Giles, F. J., & Taylor, A. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01352-x · Cited by 49
Diao, J., Gu, H., Tang, M., Zhao, J., & Cattral, M. S. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701514 · Cited by 49
PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives
Wang, Y., & Li, G. (2019) · Frontiers of Medicine · doi:10.1007/s11684-018-0674-4 · Cited by 49
Immunometabolism in the Tumor Microenvironment
Roy, D. G., Kaymak, I., Williams, K. S., Ma, E. H., & Jones, R. G. (2020) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055817 · Cited by 49
Ferrara, R., Imbimbo, M., Malouf, R. S., Paget‐Bailly, S., Calais, F., Marchal, C., & Westeel, V. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013257.pub2 · Cited by 51
Charting roadmaps towards novel and safe synergistic immunotherapy combinations
Sanmamed, M. F., Berraondo, P., Rodriguez-Ruiz, M. E., & Melero, I. (2022) · Nature Cancer · doi:10.1038/s43018-022-00401-1 · Cited by 50
Galimberti, S., Petrini, M., Baratè, C., Ricci, F., Balducci, S., Grassi, S., Guerrini, F., Ciabatti, E., Mechelli, S., Paolo, A. D., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01428 · Cited by 48
The paradox of radiation and T cells in tumors
Gough, M. J., & Crittenden, M. R. (2022) · Neoplasia · doi:10.1016/j.neo.2022.100808 · Cited by 51
Resistance to immune checkpoint inhibitors and the tumor microenvironment
Kawashima, S., & Togashi, Y. (2022) · Experimental Dermatology · doi:10.1111/exd.14716 · Cited by 50
Progresses in biomarkers for cancer immunotherapy
Lin, X., Zong, C., Zhang, Z., Fang, W., & Xu, P. (2023) · MedComm · doi:10.1002/mco2.387 · Cited by 50
The role of CD4+ T cells in tumor and chronic viral immune responses
Xie, L., Fang, J., Yu, J., Zhang, W., He, Z., Ye, L., & Wang, H. (2023) · MedComm · doi:10.1002/mco2.390 · Cited by 54
Discovery of Small Molecules for the Reversal of T Cell Exhaustion
Marro, B. S., Žák, J., Zavareh, R. B., Teijaro, J. R., Lairson, L. L., & Oldstone, M. B. A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.119 · Cited by 47
Choi, J. W., Withers, S. S., Chang, H., Spanier, J. A., Trinidad, V. L. D. L., Panesar, H. K., Fife, B. T., Sciammas, R., Sparger, E. E., Moore, P. F., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0235518 · Cited by 53
Therapeutic Targeting of Checkpoint Receptors within the DNAM1 Axis
Alteber, Z., Kotturi, M. F., Whelan, S., Ganguly, S., Weyl, E., Pardoll, D. M., Hunter, J., & Ophir, E. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1248 · Cited by 48
Marofi, F., Rahman, H. S., Achmad, M. H., Sergeevna, K. N., Suksatan, W., Abdelbasset, W. K., Mikhailova, M. V., Shomali, N., Yazdanifar, M., Hassanzadeh, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.681984 · Cited by 48
RetractedAtezolizumab for the treatment of non-small cell lung cancer
Santini, F. C., & Rudin, C. M. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1356717 · Cited by 47
Membrane Rafts in T Cell Activation: A Spotlight on CD28 Costimulation
Zumerle, S., Molon, B., & Viola, A. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01467 · Cited by 55
Kroon, P., Frijlink, E., Iglesias‐Guimarais, V., Volkov, A., van Buuren, M. M., Schumacher, T. N., Verheij, M., Borst, J. G., & Verbrugge, I. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0654 · Cited by 53
Regulation of GVHD and GVL Activity via PD-L1 Interaction With PD-1 and CD80
Cassady, K. M., Martin, P. J., & Zeng, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03061 · Cited by 48
Martínez-Usatorre, A., Sempere, L. F., Carmona, S. J., Carretero-Iglesia, L., Monnot, G., Speiser, D. E., Rufer, N., Donda, A., Zehn, D., Jandus, C., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0504 · Cited by 50
In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors
Khalil, D. N., Suek, N., Campesato, L. F., Budhu, S., Redmond, D., Samstein, R. M., Krishna, C., Panageas, K. S., Capanu, M., Houghton, S., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci128562 · Cited by 48
Tang, K., Jia, Y.-N., Yu, B., & Liu, H. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112657 · Cited by 47
Maurer, M. F., Lewis, K. E., Kuijper, J. L., Ardourel, D., Gudgeon, C. J., Chandrasekaran, S., Mudri, S., Kleist, K. N., Navas, C. L., Wolfson, M. F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29286-5 · Cited by 46
Inhibitory PD-1 axis maintains high-avidity stem-like CD8+ T cells
Hor, J. L., Schrom, E. C., Wong-Rolle, A., Vistain, L. F., Shang, W., Dong, Q., Zhao, C. N., Jin, C., & Germain, R. N. (2025) · Nature · doi:10.1038/s41586-025-09440-x · Cited by 56
Preite, S., Huang, B., Cannons, J. L., McGavern, D. B., & Schwartzberg, P. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03079 · Cited by 45
Shp-2 is critical for ERK and metabolic engagement downstream of IL-15 receptor in NK cells
Niogret, C., Miah, S. M. S., Rota, G., Fonta, N., Wang, H., Held, W., Birchmeier, W., Sexl, V., Yang, W., Vivier, É., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09431-3 · Cited by 46
König, D., & Laubli, H. P. (2020) · Pharmacology · doi:10.1159/000509081 · Cited by 49
PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies
Nishimura, C., Pulanco, M. C., Cui, W., Lu, L., & Zang, X. (2020) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.10.004 · Cited by 45
Yang, Y., Yeh, S. H., Madireddi, S., Matochko, W. L., Gu, C., Sanchez, P. P., Ultsch, M. H., Boenig, G. D. L., Harris, S. F., Leonard, B. C., et al. (2019) · mAbs · doi:10.1080/19420862.2019.1625662 · Cited by 48
Self-citationRecent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors
Kong, J., & Long, Y. (2022) · RSC Medicinal Chemistry · doi:10.1039/d1md00386k · Cited by 45
Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
Li, T., Wang, X., Niu, M., Wang, M., Zhou, J., Wu, K., & Yi, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196970 · Cited by 52
Jaeger-Ruckstuhl, C. A., Lo, Y., Fulton, E. C., Waltner, O. G., Shabaneh, T. B., Simon, S., Muthuraman, P. V., Correnti, C., Newsom, O. J., Engström, I., et al. (2024) · Immunity · doi:10.1016/j.immuni.2024.01.011 · Cited by 49
Transmembrane domain–driven PD-1 dimers mediate T cell inhibition
Philips, E. A., Liu, J., Kvalvaag, A. S., Mørch, A. M., Tocheva, A. S., Ng, C., Liang, H., Ahearn, I. M., Pan, R., Luo, C. C., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.ade6256 · Cited by 46
He, J.-C., Zhang, Z., Lv, S., Liu, X., Cui, L., Jiang, D., Zhang, Q., Li, L., Qin, W., Jin, H., et al. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.04.007 · Cited by 46
Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins
Yang, Q., Cao, W., Wang, Z., Zhang, B., & Liu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.015 · Cited by 45
Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist
Polesso, F., Weinberg, A. D., & Moran, A. E. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0222 · Cited by 45
Computational Model of Chimeric Antigen Receptors Explains Site-Specific Phosphorylation Kinetics
Rohrs, J. A., Zheng, D., Graham, N. A., Wang, P., & Finley, S. D. (2018) · Biophysical Journal · doi:10.1016/j.bpj.2018.08.018 · Cited by 42
Hanna, B. S., Yazdanparast, H., Demerdash, Y., Roessner, P. M., Schulz, R., Lichter, P., Stilgenbauer, S., & Seiffert, M. (2020) · Haematologica · doi:10.3324/haematol.2019.238154 · Cited by 45
Glinos, D. A., Soskic, B., Williams, C., Kennedy, A., Jostins, L., Sansom, D. M., & Trynka, G. (2020) · Genes and Immunity · doi:10.1038/s41435-020-00118-0 · Cited by 47
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure
Pathak, R., Pharaon, R. R., Mohanty, A. R., Villaflor, V. M., Salgia, R., & Massarelli, E. (2020) · Cancers · doi:10.3390/cancers12123851 · Cited by 46
Tumor resident regulatory T cells
Glasner, A., & Plitas, G. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101476 · Cited by 47
Hong, W. X., Sagiv-Barfi, I., Czerwinski, D. K., Sallets, A., & Levy, R. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-1382 · Cited by 43
33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)
Golinelli, G., Dominici, M., Grisendi, G., Spano, C., Rossignoli, F., & Prapa, M. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0422-y · Cited by 45
Modulation of TCR Signaling by Tyrosine Phosphatases: From Autoimmunity to Immunotherapy
Castro-Sanchez, P., Teagle, A. R., Prade, S., & Zamoyska, R. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.608747 · Cited by 44
T Cell Reprogramming Against Cancer
Katz, S. G., & Rabinovich, P. M. (2019) · Methods in molecular biology · doi:10.1007/978-1-0716-0203-4_1 · Cited by 45
Voronova, V., Vislobokova, A., Mutig, K., Samsonov, M., Peskov, K. V., Sekacheva, M. I., Materenchuk, M. Y., Bunyatyan, N. D., & Lebedeva, S. A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1035884 · Cited by 47
The impact of hypoxia on tumor-mediated bypassing anti-PD-(L)1 therapy
Mortezaee, K., Majidpoor, J., & Kharazinejad, E. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114646 · Cited by 45
Palermo, B., Franzese, O., Frisullo, G., D’Ambrosio, L., Panetta, M., Campo, G., D’Andrea, D., Sperduti, I., Nicola, F. D., Goeman, F., et al. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02846-3 · Cited by 46
Mitsuhashi, A., & Okuma, Y. (2018) · Clinical & Translational Oncology · doi:10.1007/s12094-017-1827-7 · Cited by 43
Fisicaro, P., Boni, C., Barili, V., Laccabue, D., & Ferrari, C. I. (2018) · Current Opinion in Virology · doi:10.1016/j.coviro.2018.01.003 · Cited by 44
Critical role of post-transcriptional regulation for IFN-γ in tumor-infiltrating T cells
Salerno, F., Guislain, A., Heeren, J. J. F., Nicolet, B. P., Young, H. A., & Wolkers, M. C. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1532762 · Cited by 45
Determinants of Resistance to Checkpoint Inhibitors
Tran, L. L., & Theodorescu, D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051594 · Cited by 43
Biomarkers in Immunotherapy-Based Precision Treatments of Digestive System Tumors
Zeng, Z., Yang, B., & Liao, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650481 · Cited by 44
ZAP70, too little, too much can lead to autoimmunity*
Ashouri, J. F., Lo, W., Nguyen, T. T. T., Shen, L., & Weiss, A. (2021) · Immunological Reviews · doi:10.1111/imr.13058 · Cited by 47
Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy
Lee, T.-A., Tsai, E.-Y., Liu, S.-H., Hung, S.-D. H., Chang, S., Chao, C.-H., Lai, Y., Yamaguchi, H., & Li, C. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2664 · Cited by 43
T cell-based cancer immunotherapy: opportunities and challenges
Ma, K., Xu, Y., Cheng, H., Tang, K., Ma, J., & Huang, B. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.03.054 · Cited by 47
Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again
Bucktrout, S. L., Bluestone, J. A., & Ramsdell, F. (2018) · Genome Medicine · doi:10.1186/s13073-018-0588-4 · Cited by 47
Genotype Driven Therapy for Non-Small Cell Lung Cancer: Resistance, Pan Inhibitors and Immunotherapy
Singh, S. S., Dahal, A., Shrestha, L., & Jois, S. D. S. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666190222183219 · Cited by 42
Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade
Lee, B. R., Chae, S., Moon, J., Kim, M. J., Lee, H., Ko, H. W., Cho, B. C., Shim, H. S., Hwang, D., Kim, H. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.128633 · Cited by 44
Guo, Y., Jin, Y., Wang, B., & Liu, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094766 · Cited by 44
What Happens to the Immune Microenvironment After PD-1 Inhibitor Therapy?
Wang, Q., Xie, B., Liu, S., Shi, Y., Tao, Y., Xiao, D., & Wang, W. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.773168 · Cited by 47
Wu, L., Wang, W., Tian, J., Qi, C., Cai, Z., Yan, W., Xuan, S., & Shang, A. (2022) · Journal of Cancer · doi:10.7150/jca.63991 · Cited by 46
Current Advances in PD-1/PD-L1 Blockade in Recurrent Epithelial Ovarian Cancer
Zhang, Y., Cui, Q., Xu, M., Liu, D., Yao, S., & Chen, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.901772 · Cited by 45
Kim, M. J., & Ha, S. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.767466 · Cited by 46
Carlisle, J. W., Jansen, C. S., Cardenas, M. A., Sobierajska, E., Reyes, A. M., Greenwald, R., del Balzo, L., Prokhnevska, N., Küçük, Ö., Carthon, B. C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004803 · Cited by 42
Metadata
- Authors
- Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., & Vale, R. D.
- Affiliations
- Howard Hughes Medical Institute (US)
- Genentech (US)
- University of Chicago (US)
- Corresponding author
- Mellman, Ira
- Vale, Ronald D.
- ORCID
- Venue
- Science
- Published
- 2017-03-31
- Volume
- 355
- Issue
- 6332
- Pages
- 1428-1433
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6286077
- OpenAlex
- W2592133876
- Cited by
- 1,689
- References
- 68
- Citations by year
- 2026: 121 · 2025: 158 · 2024: 201 · 2023: 203 · 2022: 193 · 2021: 218 · 2020: 224 · 2019: 159 · 2018: 143 · 2017: 63
- FWCI
- 70.99
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Chicago Biomedical Consortium
- NIH (R21AI120010, R00AI106941)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- PD-1, CD28, PD-L1, T cell costimulation, T cell receptor signaling, SHP2, receptor dephosphorylation, T cell activation, anti-PD-1 therapy, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunotherapy, Lymphocyte Activation, Mice, Inbred C57BL, Neoplasms, Phosphorylation, T-Lymphocytes, CD28 Antigens, Jurkat Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
